AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
AbbVie NYSE: ABBV was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management’s lean toward diversifying away from Humira and into a broader range of treatments has more than paid off. The takeaway is that growth is back in the immunology portfolio despite the 30% contraction in […]
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede Read More »